The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR(PDF, 524KB) and Technical Notes(PDF, 752KB) pages.



Download and Print: Download Printer-friendly PDF Download data


Table 24.22

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Both Sexes by Race

Histologya All Races White Black Asian/
Pacific Islander
American Indian
/Alaska Nativeb
Hispanicc
Count Percent Count Percent Count Percent Count Percent Count Percent Count Percent
Carcinoma 29,990 92.1% 21,430 92.7% 3,857 87.6% 4,165 93.1% 251 96.9% 5,665 95.0%
Epidermoid carcinomad (8051-8131) 298 0.9% 209 0.9% 54 1.2% 30 0.7% - - 32 0.5%
Squamous cell carcinoma (8070-8078,8083-8084) 289 0.9% 202 0.9% 54 1.2% 28 0.6% - - 28 0.5%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941) 26,666 81.9% 18,927 81.9% 3,376 76.6% 3,930 87.9% 222 85.7% 5,027 84.3%
Adenocarcinoma, NOS (8140) 15,278 46.9% 11,304 48.9% 1,872 42.5% 1,878 42.0% 121 46.7% 2,359 39.6%
Adenocarcinoma, intestinal type (8144) 2,774 8.5% 1,649 7.1% 447 10.1% 629 14.1% 28 10.8% 558 9.4%
Carcinoma, diffuse type (8145) 1,332 4.1% 824 3.6% 155 3.5% 320 7.2% 17 6.6% 349 5.9%
Linitus plastica (8142) 166 0.5% 125 0.5% - - 25 0.6% - - 43 0.7%
Mucinous adenocarcinoma (8470-8473,8480,8482) 415 1.3% 291 1.3% 59 1.3% 56 1.3% - - 69 1.2%
Mucin-producing adenocarcinoma (8481) 105 0.3% 78 0.3% 19 0.4% - - - - 22 0.4%
Signet ring adenocarcinoma (8490) 5,318 16.3% 3,773 16.3% 639 14.5% 810 18.1% 46 17.8% 1,374 23.0%
Other adenocarcinomase 1,278 3.9% 883 3.8% 171 3.9% 204 4.6% - - 253 4.2%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671) 2,371 7.3% 1,837 7.9% 329 7.5% 122 2.7% 19 7.3% 506 8.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022) 655 2.0% 457 2.0% 98 2.2% 83 1.9% - - 100 1.7%
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582) 80 0.2% 64 0.3% - - - - - - - -
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539) 2,316 7.1% 1,488 6.4% 515 11.7% 285 6.4% - - 240 4.0%
Unspecified (8000-8005) 174 0.5% 126 0.5% 22 0.5% 19 0.4% - - 46 0.8%
Totald 32,560 100.0% 23,108 100.0% 4,405 100.0% 4,473 100.0% 259 100.0% 5,962 100.0%

Footnotes:

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Percents may not sum to 100 due to rounding.

a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

e Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Page Navigation: << Previous Next >>


The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.